Table 2 Baseline characteristics between paclitaxel-sensitive and–resistant patients in the training set
|  | Paclitaxel-sensitive (N = 93, %) | Paclitaxel-resistant (N = 137, %) | P |
|---|---|---|---|
Age (y) | Â | Â | Â |
Median, years (range) | 64 (37–87) | 64 (25–91) | 0.910 |
< 40 years, n (%) | 3 (3.2) | 5 (3.6) | 0.833 |
\( \ge \)70 years, n (%) | 28 (30.1) | 46 (33.6) | Â |
Sex | Â | Â | 0.116 |
Male | 57 (61.3) | 98 (71.5) | Â |
Female | 36 (28.5) | 39 (28.5) | Â |
Histology | Â | Â | 0.072 |
Intestinal type | 51 (54.8) | 92 (67.2) | Â |
Diffuse type | 42 (45.2) | 45 (32.8) | Â |
Clinical settings | Â | Â | 0.132 |
Initially metastatic disease | 57 (61.3) | 97 (70.8) | Â |
Recurrent disease | 36 (38.7) | 40 (29.2) | Â |
Prior gastrectomy | 56 (60.2) | 64 (46.7) | 0.059 |
Prior trastuzumab use | 20 (21.5) | 20 (14.6) | 0.215 |
Duration of prior 1st -line fluoropyrimidine plus platinum– based chemotherapy |  |  | 0.034 |
< 3 months | 17 (18.3) | 40 (29.2) |  |
≥ 6 months | 44 (47.3) | 43 (31.4) |  |